Florida-Based Science and Technology Company Crescel Announces Landmark Peer-Reviewed Medical Publication | The AI Journal
PubMed-Indexed Clinical Study Demonstrates Superior Results vs. the Leading Prescription Standard of Care for Rosacea, Highlighting the Potential for Better Outcomes and More Affordable Healthcare,. . .
PubMed-Indexed Clinical Study Demonstrates Superior Results vs. the Leading Prescription Standard of Care for Rosacea, Highlighting the Potential for Better Outcomes and More Affordable Healthcare, /PRNewswire/ — Crescel LLC, a Florida-based innovative science and technology company, today announced publication of its landmarkPubMed-indexed, peer-reviewed clinical studyshowing that its biobotanical technology producedstatistically significant improvements over the leading prescription standard of care for rosaceain a randomized, double-blind, controlled clinical trial. Published in theJournal of Cosmetic Dermatology, the study represents a major scientific milestone for the company’s pioneering proprietary microemulsion technology platform and a significant advancement in formulation science. The study demonstrated statistically significant improvements in facial redness and inflammatory lesions, with Crescel® Skin Renewal Cream reducing facial redness by54% compared with 23% for the prescription standard of care and inflammatory lesions by 74% compared with 17%, while demonstrating anexcellent safety profile, with no negative side effects observed. Rosacea affects more than400 million people worldwide, making it one of the most common chronic inflammatory skin conditions. Beyond its clinical findings, Crescel believes the publication demonstrates the broader potential ofAmerican-developed,non-pharmaceutical healthcare innovations to improve health outcomes while helping address one of the nation’s most pressing challenges—healthcare affordability. “Healthcare systems around the world are searching for innovative solutions that improve outcomes while reducing long-term costs,”saidPeter J. Passalacqua, Jr. , Co-Founder, Chairman & CEO of Crescel. “Our peer-reviewed publication validates years of scientific research and reinforces our belief that breakthrough biobotanical technologies can play an increasingly important role in the future of healthcare. ”Beyond the published clinical trial, Crescel has also demonstrated promising real-world clinical outcomes across multiple high-cost skin conditions, further reinforcing the broader potential of its proprietary microemulsion technology platform. “This is one of the most exciting medical advancements I have seen in my 30 years of practicing rehabilitation medicine,”saidDr. Roberta Shapiro, Assistant Clinical Professor, Columbia University Medical Center, Department of Rehabilitation and Regenerative Medicine, and Chief Medical Officer of Crescel. “Crescel’s healing capabilities are exceptional. This innovative technology has the potential to improve care while expanding access to safe, effective, non-pharmaceutical options. ”The complete study,“Efficacy, Tolerance, and Safety of a Novel Botanical Anti-Inflammatory Moisturizer in Rosacea: Results From a Double-Blinded, Randomized Controlled Trial,”is available throughPubMedand theJournal of Cosmetic Dermatology. Study LinksJournal of Cosmetic Dermatology (Full Publication):https://onlinelibrary. wiley. com/doi/10. 1111/jocd. 70910PubMed Index:https://pubmed. ncbi. nlm. nih. gov/42163060/For more information about Crescel, visitwww. crescel. com. View original content to download multimedia:https://www. prnewswire. com/news-releases/florida-based-science-and-technology-company-crescel-announces-landmark-peer-reviewed-medical-publication-302833448. htmlSOURCE Crescel LLC